Recent reports have demonstrated that HDAC inhibitors enhance response to immune checkpoint blockade in triple negative breast cancer, lung adenocarcinoma, melanoma, and multiple myeloma (27–30). Here, HDAC9 is linked to plasma cell myeloma.